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Therapeutic Approach to Advanced 
Pancreatic Carcinoma
Michael M. Vaslamatzis, MD, Ileanna Roilou, MD,  
Nektarios Alevizopoulos, MD
A B S T R A C T
Pancreatic carcinoma, a chemoresistant disease, still remains a therapeutic chal-
lenge in oncology. A variety of cytotoxic agents have been tried with promising or 
disappointing results. Gemcitabine as a single agent or combined chemotherapy is 
the mainstay therapeutic approach in locally advanced or metastatic disease. Newer 
agents, such as tyrosine kinase inhibitors and monoclonal antibodies (bevacizumab, 
erbitux) are widely used nowadays in modern therapeutic algorithms with promising 
results.
I N T R O D U C T I O N
Pancreatic cancer, an extremely lethal malignant disease, constitutes the fourth 
most common cause of cancer death. The annual diagnosis of this disease has stead-
ily increased worldwide. During 2009 in the United States of America, 42470 new 
pancreatic cancer cases and 35240 related deaths were documented.1 Due to lack of 
specific symptoms at the onset of the disease, the majority of patients present with 
locally advanced or metastatic inoperable disease. Thus, the overall survival rate for 
all stages combined is extremely poor, less than 1% at 5 years. Median survival time is 
about 8-12 months for locally advanced inoperable disease and 3-6 months for extensive 
metastatic disease.2,3 Over the past decades, the cytotoxic drug gemcitabine (Gem) has 
proven its efficacy in improving the quality of life (QOL) in patients with pancreatic 
cancer, thus becoming the mainstay therapy, albeit its moderate antineoplasmatic ef-
fect.4 All chemotherapeutic options for advanced pancreatic malignant disease cover 
an extended era of two periods, preceding and following Gem. Many phase II trials 
tested Gem combinations with various chemotherapeutic agents as front-line therapy 
for advanced disease; however, none of them proved superior to single Gem except 
erlotinib.5,6 The addition of capecitabine, a platinum salt compound, and targeted 
monoclonal antibodies, including bevacizumab and cetuximab which were extensively 
investigated, provided modest interesting advances but failed to offer a clear survival 
benefit. Erlotinib, a new tyrosine kinase inhibitor, gained FDA approval for the small 
overall survival benefit recorded when combined with Gem.3,7,8
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AbbreviAtions
EGFR = epidermal growth factor 
receptor
FDR = fixed dose rate
5-FU = 5-fluorouracil
Gem = gemcitabine
LV = leucovorin
PFS = progression-free survival
QOL = quality of life
RR = response rate
TTP = time to progression
VEGF = vascular endothelial growth 
factor
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C H e M O T H e R A P e U T I C  T R e A T M e N T  F O R 
A D v A N C e D  P A N C R e A T I C  C A N C e R
Advanced pancreatic cancer is defined as tumour encas-
ing the superior mesenteric artery, celiac artery, aorta or 
inferior vena cava which represents the unresectable status 
of the disease. The role of radiotherapy, however, remains 
controversial and is under investigation in a variety of trials 
studying the appropriate chemotherapy combination with 
radiation, demonstrated by the gastrointestinal tumour study 
group, the European organization for research and treatment 
of cancer, the European study group for pancreatic cancer and 
the American College of Surgeons oncology group).9 This re-
view will not address all the trials highlighting the concurrent 
use of chemoradiation therapy for the advanced pancreatic 
malignant disease.10 We will focus on the chemotherapeutic 
agents used as single agent or combination therapy in first-line 
therapeutic setting for locally advanced disease.
S I N G L e  A G e N T  C H e M O T H e R A P y
Chemotherapeutic treatment for advanced pancreatic 
cancer with single agent cytotoxic drugs has been thoroughly 
studied, but none has provided overall response greater than 
10%. Capecitabine, 5-fluorouracil (FU), anthracyclines, 
docetaxel, camptothecins ifosfamide, streptozocin and Gem 
have been tried as single agent and in variable combination 
settings. These therapies are detailed below.
5 - F L U O R O U R A C I L  ( 5 - F U )
5-Fluorouracil has been used as monotherapy since 1950 
providing overall response rates (RR) even up to 67% in pa-
tients with advanced pancreatic cancer.11 The biological mod-
eration of 5-FU with concomitant use of leucovorin (LV) did 
not manage to demonstrate higher overall RR (RR reported: 
0-9%). Bolus intravenous infusion used in earlier studies did 
not extend the overall survival more than 24 weeks 12- 14.
C A P e C I T A B I N e
Capecitabine, an oral fluoropyrimidine prodrug, which is 
absorbed in the intestinal tract and converted to 5-FU through 
three step enzyme- mediated reactions, has been examined 
alone in front-line therapy. Critical role to the metabolism of 
capecitabine has the last enzymic product of the conversion, 
thymidine phosphorylase, which is present at higher concen-
trations in the neoplasm than in normal cells, providing basis 
for better clinical action with fewer side-effects. Capecitabine, 
as first-line monotherapy, was evaluated in a study of 42 pa-
tients enrolled with advanced pancreatic malignancy. Objec-
tive partial response was documented in 3 patients (7%), and 
24% showed clinical benefit. The main toxicity reported were 
hand-foot syndrome (grade III), nausea and diarrhea in 17%, 
10% and 12% respectively. 15
A N T H R A C y C L I N e S
Anthracyclines, although widely known for their antican-
cer potential, have been of limited efficacy in monotherapy 
for advanced pancreatic cancer. The novel Gastrointestinal 
Tumour Study Group, 30 years ago, considered adriamycin 
in first- and second-line treatment. A minimal therapeutic 
response has been recorded in 2 out of 15 previously untreated 
patients compared with 0 out of 10 patients with previously 
treated disease.16. Later, the European Organization for Re-
search and Treatment of Cancer study enrolled 41 patients to 
receive epirubicin as a single therapeutic agent. The overall 
response rate reported was 24% and the median overall sur-
vival was only three months.17
S T R e P T O z O C I N  A N D  I F O S FA M I D e
Streptozocin and Ifosfamide have proved limited antitu-
mor efficacy in terms of single agent first-line treatment for 
advanced pancreatic cancer. Studies conducted over the past 
decades with streptozocin and ifosfamide monotherapy have 
reported an overall response of 11% (3 of 27 patients included) 
with streptozocin and 7% - 10% with ifosfamide respectively.18 
Years later two phase II trials again did not manage to present 
median survival time greater than 12 weeks.19, 20
T A x A N e S
Taxanes, especially docetaxel, have also proved limited 
efficacy in first-line chemotherapeutic single-agent approach 
in advanced disease. A phase II study by Androulakis et al, 
conducted with docetaxel offered as single agent treatment in 
33 patients, reported only 6% RR, and one year documented 
survival benefit of 36% was attributed to disease stabiliza-
tion.21 Rougier et al, one year later, enrolled 40 patients 
with advanced pancreatic cancer, and tried docetaxel (100 
mg/m2 every 3 weeks) as a single agent. An overall RR of 
15% - 38% was observed.22. Many other relevant studies have 
also confirmed the minimal benefit associated with docetaxel 
monotherapy. 23-25
C A M P T O T H e C I N S
Camptothecins including topotecan, irinotecan and 
9-nitro-camptothecin (rubitecan), have shown limited efficacy 
in advanced pancreatic cancer as single agent treatment; RR 
of 0-29% and a median survival of 4-6.5 months have been 
reported in the literature. Hence, camptothecins in combina-
tion with other drugs are thoroughly studied in ongoing clinical 
trials aiming for better overall responses and clinical benefit.26
G e M C I T A B I N e
Gemcitabine monotherapy in advanced pancreatic cancer 
is the only approved cytotoxic treatment providing noticeable 
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improvement of survival and enhancing quality of life (QOL). 
A trial by Burris et al has established Gem as the standard of 
care for the first-line setting of advanced disease considering 
the survival benefit of Gem monotherapy over 5FU-based pal-
liative therapy.4,27 The trial enrolled 126 patients with advanced 
disease, randomizing them either to a Gem infusion arm or to 
a 5-FU arm. The Gem arm showed better survival rates (18% 
vs. 2%), higher median survival (5.7 vs. 4.4 months, p=0.0025) 
and a satisfactory clinical benefit (24% vs. 5%, p=0.0022). The 
clinical benefit, representing QOL, related to weight gain, 
pain relief, and improvement in patients’ activity. Later phase 
III studies presented a median survival of 5-6 months and an 
annual survival rate up to 20 %, revealing again the promising 
activity of Gem and its superiority to best supportive care.5 
A vast majority of studies have been employed to determine 
the best administrative way of gemcitabine (bolus infusion, 
prolonged administration or fixed dose rate) aiming to exceed 
the survival advantage. The administration of Gem in a fixed 
dose rate (FDR) of 10 mg/m2 per minute, maximizes the 
intracellular concentrations of the active phosphorylated 
Gem metabolite, thus achieving a pharmacokinetic advantage 
of the maximum tolerated dose increase.28-30 Based on the 
above data, a phase II trial randomly distributed 92 enrolled 
patients either to FDR Gem (1500 mg/m2 with infusion rate 
of 10 mg/m2/min on the days 1, 8, 15 every 4 weeks) or high 
dose Gem (2200 mg/m2, administered over 30 minutes IV on 
the days 1, 8, 15 every 4 weeks). The primary trial endpoint, 
time to the treatment failure, was similar for both arms, but 
the median survival reported was 8 months in the FDR arm 
vs 5 months in the compared arm.31 The stable infusion rate 
resulted in significant increase of the intracellular Gem form, 
thus accounting for the difference. Thus, significantly higher 
intracellular levels were achieved and a better overall median 
survival was demonstrated in patients with advanced disease 
who received FDR-Gem.32
C O M B I N A T I O N  T H e R A P y
Many combinations of chemotherapeutic agents have been 
tried in patients with advanced pancreatic cancer providing 
higher overall response rate without a clear clinical benefit 
over single agent Gem.5,33-40 Literature review indicates that 
all possible chemotherapeutic combinations have been tested 
without dampening the antitumor activity of the single agents 
(5F-U, Gem, oxaliplatine, docetaxel, platinum, irrinotecan). 
In this review, we present an overview of the data published 
concerning the combination treatments. It is noteworthy that 
only two phase III studies, comparing Gem monotherapy to 
combined erlotinib or capecitabine, respectively, have con-
firmed a considerable overall survival benefit.41,42
C O M B I N A T I O N S  B A S e D  O N  5 - F U
Randomized well-designed trials have failed to demon-
strate survival benefit with 5-FU based chemotherapy. Only 
higher response rates have been reported with combined 
therapy in advanced pancreatic cancer governing the necessity 
of other treatment options.4,43-52 All the relevant studies have 
been reported by Cullinan et al who have compared three 
chemotherapeutic regimens in advanced disease. A phase 
II randomized trial analyzed data in 385 patients assigned 
to receive either 5-FU alone or 5-FU plus doxorubicin, or 
5-FU plus doxorubicin and mitomycin (FAM). The objective 
response rate and the median survival recorded did not differ 
in the three arms. Median survival reported was 5.5 months 
for all therapies.47 Another trial, published by Cullinan et al, 
assigned 187 patients to three therapeutic arms; the arm of 
5-FU alone, the arm of 5-FU plus doxorubicin plus cisplatin 
and the third arm of 5-FU plus cyclophosphamide, metho-
trexate, vincristine and mitomycin. None of the combinations 
presented better overall survival compared to 5-FU mono-
therapy.50 More recently the Eastern Cooperative Oncology 
Group E2297 trial compared the IV administration of Gem 
(1000 mg/m2) and 5-FU (600 mg/m2, days 1,8,15 every 4 weeks) 
vs only Gem (1000 mg/m2) in 322 patients.33 The study showed 
a trend of better survival in the combination group (6.7 vs 5.4 
months, p=0.09), but not at a statistically significant level. Ad-
ditionally, 5-FU was given in bolus infusion, which has proven 
to be of lower efficacy than the infusion administration and 
this must be taken into consideration in results analysis. In the 
CONCO-002 study, 466 patients were randomized to receive 
either 5-FU/LV and Gem or Gem alone. There were no dif-
ferences noted in the two arms, but the median survival was 
better in the combination group (6.2 vs 5.85 months, p=0.68), 
though not statistically significant.35
5 - F U  C O M B I N A T I O N S  v e R S U S  B e S T 
S U P P O R T I v e  C A R e
Two large meta-analyses have compared 5-FU based 
combinations to best supportive care.53,54 In the Cochrane 
meta-analysis, 5 studies with 7043 patients enrolled were 
included. Chemotherapy treatment reduced annual mortality 
quite significantly (p= 0.00001, odds ratio 0.37). Concurrent 
chemoradiation induced annual survival rates of 58% com-
pared to 0% (p=0.001) of the best supportive care group.53 
No differences in the annual mortality were found in the arm 
with single agent 5-FU compared to the combination arm 
(odds ratio 0.90). Trials comparing single-agent therapies to 
single Gem (odds ratio 1.34, p=0.17) and Gem monotherapy 
to combined (odds ratio 0.88) have also been analysed.
C O M B I N A T I O N S  O F  5 F U  w I T H  I R I N O T e C A N 
A N D  O x A L I P L A T I N
The combination of 5-FU with LV and irinotecan with or 
without oxaliplatin has been investigated in a trial including 47 
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patients with locally advanced pancreatic cancer. The regimen, 
named “Folfirinox,” was given every 2 weeks (oxaliplatin 85 
mg/m2 day 1 for 2 hours; irinotecan 180 mg/m2 day 1 for 90 
min; LV 400 mg/m2 for 2 hours and then; 5-FU 400 mg/m2 
bolus and then, 2400 mg/m2 in continual 46-hour infusion). 
An overall good response was recorded in 12 (26%) patients, 
and complete response in 2 patients (4%). The median time to 
progression (TTP) and the median overall survival reported 
was respectively 8.2 and 10.2 months. Grade 3 or 4 neutro-
penia was noted in 52% (febrile neutropenia in 2 patients), 
whereas nausea, vomiting, diarrhea and neuropathy were 
observed in 20%, 17%, 17% and 15% respectively.55 Ghosn 
M et al investigated the role of FOLFOX (5-FU with LV and 
oxaliplatin combination) in 30 patients with advanced cancer. 
Overall response in 8 (27%) patients, a median TTP of 4 
months and median survival 7.5 months was reported. Grade 
3 or 4 toxicity including neutropenia, thrombocytopenia and 
anemia occurred in 27%, 10% and 10% of patients respec-
tively.56 In another trial, 40 patients were treated with the 
FOLFIRI combination (5-FU with LV and irinotecan). The 
overall response rate and the stable disease rate achieved was 
37.5% and 27.5%, respectively. The median TTP and overall 
survival reported were respectively 4 and 7.5 months. Grade 
3 or 4 toxicity included neutropenia, nausea, vomiting and 
diarrhea in 35%, 27% and 15% respectively.57 To clarify the 
possible benefit of the above chemotherapeutic combinations, 
phase III studies should be designed and comparisons with 
Gem monotherapy should be done.
T H e R A P I e S  w I T H  O T H e R  C O M B I N e D  A G e N T S
The combination of cisplatin and cytarabine has been 
investigated in an early study. Partial response in 7 out of 18 
patients with measurable disease and median response dura-
tion up to 6.2 months has been reported.58 A more recent 
study combined cisplatin (100 mg/m2, on day 1), cytarabine 
(2 mg/m2 x 2 IV, day 1) and 5-FU (250 mg/m2 in continuous 
intravenous administration daily) with caffeine (400 mg/m2, 
subcutaneously post cytarabine administration) and enrolled 
30 patients with advanced pancreatic cancer. The cycle was 
repeated every 28 days and the median number of cycles 
given was 3 per patient. Complete and partial response was 
noted in 2 and 3 patients with overall response of 16.7% noted 
(95% confidence interval 6.8-32.4%). A median survival of 5 
(0.3-32.4) months was reported. It is worth mentioning that 
16.7% and 10% of patients were alive after one and two years 
respectively. However, the observed hematological toxicity of 
the combination limited its use.59
C O M B I N A T I O N S  B A S e D  O N  G e M C I T A B I N e
Gemcitabine (Gem) has been the cornerstone agent in all 
combinations designed to treat advanced pancreatic cancer. 
Four metanalyses have investigated the potential therapeutic 
advantage of gemcitabine-based combinations over mono-
therapy.53,54,60-62 Two of them did not prove survival superiority 
of the combined Gem over Gem alone while the other two 
insisted on significant survival benefit for the groups of com-
bined therapy.53,54,60-62 It is of interest that the latest analyses 
were conducted by two irrelevant scientific groups, and showed 
an ideal rate of hazard ratio for the deaths in the combined arm 
(HR 0.91, 95% confidence interval 0.85-0.97). The diversity 
of the final results of the four metanalyses is attributed to 
European study results which were incorporated in the final 
analysis. This European study randomized patients to single 
gemcitabine and to gemcitabine plus/minus capecitabine 
arm. Results were announced at the 13th European Cancer 
Conference Meeting in 2005, and were published individu-
ally in 2007 favouring the combined treatment arm.63 This 
European study has not been included in the analyses of the 
two previous metanalyses. All treatment combinations based 
on gemcitabine are described in Table 1.
TABLe 1. Treatment Combinations Based on Gemcitabine (Gem)
Study Patients (No.) Chemo-drugs Overall Survival (mos) p value PFS (mos) p value
Berlin et al33 322 Gem+FU
Gem
6.7
5.4
0.09 3.4
2.2
0.022
Herrmann et al36 319 Gem+Cap
Gem
8.4
7.4
0.2 4.8
4
0.02
Heinemann et al39 219 Gem +cisplatin
Gem
7.6
6
0.12 5.3
3.1
0.053
Louvet et al38 326 Gem+oxaliplatin
Gem
9
7.1
0.13 5.8
3.7
0.04
Rocha et al34 342 Irinotecan+ Gem
Gem
6.3
6.6
0.78 3.5
3
0.35
Cap = capecitabine; FU = 5-fluorouracil; Gem = gemcitabine; PFS = progression-free survival
28
HOSPITAL CHRONICLES 6(1), 2011
G e M C I T A B I N e  C O M B I N e D  T O  5 - F U
The combination of gemcitabine with 5-FU, administered 
as a bolus or in infusion settings, has been attempted. The 
three phase III studies conducted to confirm the optimal re-
sults of the previous phase II failed to prove any benefit from 
the combined administration of Gem with 5-FU (± biological 
moderation with LV) over the single Gem therapy.33,35,64
C I S P L A T I N  P L U S  G e M C I T A B I N e
All preclinical studies designed to treat advanced disease 
with the combination of cisplatin and Gem supported their 
synergetic action. It is claimed that the Gem prodrug enhances 
increased formation of cisplatin-DNA complexes breaking 
the mechanisms to cisplatin resistance. The subsequent in-
corporation of Gem triphosphate form in DNA complexes 
is platinum action related.65, 66 Although well established, the 
basis of anticancer action, three phase III studies investigat-
ing the role of the combination cisplatin /gem failed to favour 
better survival.39, 67, 68
C O M B I N A T I O N  O F  C I S P L A T I N ,  e P I R U B I C I N , 
5 - F U  A N D  G e M C I T A B I N e  ( P e F G )
Reni et al in a phase II trial studied the PEFG combination 
(cisplatin, epirubicin, 5-FU and gemcitabine) in 49 patients 
with advanced pancreatic cancer. PEGF was repeated every 
28 days. Overall response rates up to 58%, clinical benefit in 
78%, a median time-to-progression (TTP) up to 7.5 months 
and a median survival time of 11 months have been reported. 
Neutropenia (grade 3-4) was observed in almost half of the 
cycle.69 Another multicenter phase III study later compared 
the PEFG arm to the Gem single agent. The PEFG regimen 
showed higher overall response rate (39% vs 9%) and a me-
dian TTP up to 4 months in 104 patients enrolled. Annual 
survival rates recorded did not differ in the arms (39% vs 21%) 
although the 2-year survival rate (12% vs 2%) was statistically 
significantly different. Hazard ratio for the deaths recorded 
was significantly lower for PEFG-treated patients (0.65; 
95% confidence interval 0.43-0.99, p=0.047). Hematological 
toxicity included neutropenia and thrombocytopenia with 
the combined treatment arm presenting higher rates (43% 
vs 14%) of neutropenia (grade 3 or 4) and thrombocytopenia 
(30% vs 1%).70
C O M B I N A T I O N  O F  G e M C I T A B I N e  w I T H 
I R I N O T e C A N
All phase II and III trials administering irinotecan as a 
single agent or combined with Gem have reported its minimal 
therapeutic value.71,72
C O M B I N A T I O N  O F  G e M C I T A B I N e  A N D 
D O C e T A x e L
All literature reported phase II studies evaluating the 
anticancer efficacy of docetaxel combined to Gem provide 
satisfactory response rates. Response rates up to 12-18%, 
median overall survival of 4.7-8.9 mo and myelotoxicity of 
grade 3-4 neutropenia have been reported.73-76 Apart from 
the phase II trial of Cascinu et al with 18 patients enrolled 
who presented only one partial response and claimed grade 3 
fatigue as major side-effect in 9 patients, the remaining trials 
reported encouraging results.76 Phase III trials, have not yet 
been published.
C A P e C I T A B I N e  P L U S  G e M C I T A B I N e
Capecitabine combined with Gem as first line therapy has 
been supported by the National Cancer Research Network 
(NCRN) of the Upper Gastrointestinal Cancer Clinical Study 
Group. It is based on the preliminary results of a randomized 
trial of 533 patients treated either with Gem monotherapy or 
in combination with capecitabine.7 Overall response rates of 
14.2% for the group of the combined therapy (GEM-CAP) vs 
7.1% of monotherapy (p<0.008), median survival 7.4 versus 6 
months (hazard ratio 0.8, p=0.014) and annual survival rates 
26% and 19% respectively have been reported. Neutropenia, 
thrombocytopenia, diarrhea and hand – foot syndrome as 
the toxicity profile were more frequently encountered in the 
combined treated arm. Many arguments have been raised 
against the trial, based on the short period of final results 
collection and publishing. Investigators have been troubled 
by the negative results of prior phase III trials testing the 
Gem combination with fluoropyrimidines.33,35 Hermann et 
al in another noteworthy trial including 316 patients, studied 
Gem monotherapy vs. combined with capecitabine. The me-
dian survival time was longer in the combination arm (8.4 vs 
7.3 months), although not statistically significant (p=0.314). 
A basic difference from the NCRN study was the rest period 
between the repeated cycles resulting in less intensive but 
higher tolerability of GEM-CAP.36 Bernard et al supported 
the clinical benefit response and QOL in patients treated 
with GEM-CAP or Gem alone. Of 319 patients enrolled, 19 
% of patients receiving the combination therapy and 20% 
the Gem alone group presented with better clinical response 
and median time duration of 9.5 and 6.5 weeks, respectively.78
O x A L I P L A T I N  P L U S  G e M C I T A B I N e
Oxaliplatin, a platinum compound, showed to be efficient 
and well tolerated in combination with Gem by patients with 
advanced pancreatic cancer.78 In a phase III GERCOR/
GISCAD Intergroup study with randomized distribution 
of 313 patients with advanced carcinoma, the combination 
FDR-Gem with oxaliplatin (GEMOX) was comparatively 
tested with Gem as a single agent. Although, not any sig-
nificant improvement in the overall response (27% vs 17%), 
in the median progression free time (5.8 vs 3.7 months) and 
in the clinical benefit for patients offered by GEMOX, the 
median survival time observed was 9 vs 7.1 months in both 
the arms.38 Two variables, the FDR-gem administration vs 
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the 30-minute infusion and the oxaliplatin administration vs 
non-oxaliplatin were considered in analysis of the trial. It is 
troublesome if the results are associated with different Gem 
administration, or with the concomitant use of oxaliplatin, or 
with both of them. The protocol ECOG 6201 was designed 
to answer questions raised from earlier studies7,32,38 and all 
primary results were announced at the 2006 ASCO Confer-
ence. As numerous previous studies, the protocol ECOG 6201 
showed very limited median survival benefit, with a second 
chemotherapeutic agent added to Gem and also proved that 
the administration of FDR-Gem was of limited extra benefit 
with increased toxicity.3,7,71
N e w e R  T A R G e T e D  T H e R A P I e S  I N  A D vA N C e D 
PA N C R e A T I C  C A N C e R
The identification of molecular mechanisms implicated 
in tumour growth, invasion, metastasis, angiogenesis and 
resistance to apoptosis of pancreatic cancer has led to the 
development of targeted molecular agents, designed to disable 
the essential cellular pathways. Clinical trials have been con-
ducted to investigate the therapeutic efficacy of the standard 
Gem treatment in combination with all the new molecular 
agents. Most of the published trials have failed to show better 
survival benefit over the gained by Gem single agent. Erlotinib, 
the only tyrosine kinase inhibitor, exceptionally presented a 
two-week better median survival.79,80
G e M C I T A B I N e - B A S e D  C H e M O T H e R A P y  
w I T H  M O L e C U L A R  T A R G e T e D  A G e N T S
Gemcitabine and Cetuximab
The epidermal growth factor receptor (EGFR) promotes 
ongogenic activities in human cells like uncontrolled prolif-
eration, angiogenesis and apoptosis inhibition, in terms of 
inappropriate activation or overexpression. The EGFR has 
been correlated with poor prognosis in case of overexpres-
sion in the tumours; thus it has been investigated as a pos-
sible target for systemic therapy. All preclinical data suggest 
that EGFR inhibitors may increase the antitumor activity of 
Gem in case they are incorporated in a therapeutic regimen. 
Cetuximab, a monoclonal antibody targeting the EGFR, in 
combination with Gem has been investigated in a phase II 
trial with 41 patients. The reported response rate of 12.2% 
and the disease stabilization achieved in 63.4% led to a 
phase III trial design.81,82 The Southwest Oncology Group 
(SWOG, SO205) conducted this phase III trial attempting to 
show better survival benefit over the standard Gem therapy. 
Seven-hundred thirty-five patients enrolled were randomized 
to receive either Gem or Gem-cetuximab. A median survival 
of 6 months in the Gem arm versus 6.5 in the combination 
arm, and progression-free survival (PFS) of 3 and 3.5 months 
respectively have been reported. 81,82.
Gemcitabine and Erlotinib
Moore et al have investigated the role of a tyrosine kinase 
inhibitor, erlotinib, in advanced pancreatic cancer disease via a 
III phase trial including 569 patients.83 The randomly assigned 
patients to Gem - erlotinib or standard Gem treatment were 
analyzed and a statistically significant improvement of overall 
survival (6.37 vs 5.91 months p=0.0038) and PFS was reported. 
The erlotinib arm showed a median survival of 6.24 months 
and 1-year survival rate of 23% compared to 5.91 months and 
17% of the Gem arm. Regarding QOL no significant differ-
ence was noted in both arms. Skin and gastrointestinal toxicity 
ranged up to 6% in the erlotinib arm versus 1% to the control. 
The skin rash grading was claimed to correlate positively with 
control disease regardless of the EGFR status expression in 
the tumour section.
Gemcitabine and Bevacizumab
Angiogenesis principally mediated by the vascular en-
dothelial growth factor (VEGF) family of proteins is an ap-
pealing target of therapy Bevacizumab, a humanized antibody 
against VEGF, has been incorporated in combination treat-
ments of advanced pancreatic cancer and examined in a num-
ber of clinical trials. Kindler H et al, in a phase II study, tried 
the combination of bevacizumab to standard Gem and showed 
response rate of 19% whereas Cancer and Leukemia Group 
B (GALGB) in a phase III randomized trial did not show any 
survival improvement on bevacizumab addition to Gem.84-86 
The bevacizumab arm presented 5.7 month median survival 
vs 6.0 months in the control arm. The reported PFS was 4.8 
months vs 4.3 months respectively. Although the addition of 
bevacizumab to Gem did not confer better overall survival, 
the investigators insisted on the possible effective antitumor 
activity of the VEGF antibody. Another trial, the AVITA, with 
607 patients enrolled, tested a triple therapy with bevacizumab 
/gemcitabine and erlotinib aiming to demonstrate a survival 
benefit. Progression-free survival was significantly improved 
with a month prolongation but no overall survival benefit was 
found.84-90 Bevacizumab was reported to be safe and toler-
ant with no major adverse events documented (thrombosis, 
epistaxis, bleeding, perforation, hypertension, proteinuria). 
Other trials have been conducted to examine the combination 
of bevacizumab with other agents or treatment modalities of 
pancreatic cancer, but have not succeeded in demonstrating 
any benefit. Fogelman et al studied a three-agent (gemcitabine, 
oxaliplatin and bevacizumab) chemotherapeutic regimen in 
advanced disease and reported 1-year survival rate of 40% 
and a response rate of 39%.87 Gem and oxaliplatin with 
bevacizumab addition has also been examined in another 
phase II study by Kim et al with 82 enrolled patients.88 The 
6-month survival was 65%, the median overall survival was 
8.1 months and the time to progression was reported at 5.7 
months. The concomitant monoclonal antibody treatment 
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age to show some biological activity.94-97 Bortezomib, a proteo-
some inhibitor of NFKB, failed to show any benefit when tried 
in a phase II trial as well.98
T H e  C y C L O - O x y G e N A S e  PA T H wA y  ( C O x )
The cyclo-oxygenase receptor (Cox2) inducible by growth 
factors, cytokines, and other tumour promoters is overex-
pressed in 90% of pancreatic cancer cells. The Cox- medi-
ated mechanisms in pancreatic cancer proliferation are too 
complex, implying various mitogenic signalling pathways and 
molecules mediating resistance to apoptosis. Chuang et al 
reported in 2008 the antitumor action of celecoxib (COX2 
inhibitor) but all phase II trials of its combination with Gem 
did not finally give promising results.99 Also, no significant 
benefit has been reported by Dragovich et al in another phase 
II trial.100 A phase III trial of Gem, celecoxib and curcumin 
is in progress.
O R T H e R  T A R G e T e D  A G e N T S
Farsenyle transferace inhibitor, tipifarnib, and matrix 
metalloproteinase inhibitor, marimastat, have been tested in 
pancreatic cancer treatment but with no survival benefit.101-103 
The agent AMG655,104 a humanized antibody targeting human 
death receptor 5 (DR5) activating caspases, leading to apopto-
sis in tumor cells, has been intensively studied for its antitumor 
activity in a phase I trial. Four of the seven enrolled patients 
have reduced CA19-9 levels >70%, a median progression-free 
survival of 5.3 months and a 6-month survival rate up to 76% 
have been reported. The phase II randomized trial testing the 
AMG655 in addition to Gem although completed has not yet 
reported the results.104
T R e A T M e N T  O P T I O N S  F O R 
G e M C I T A B I N e - R e S I S T A N T  
P A N C R e A T I C  C A N C e R
While a standard of care for front-line treatment of 
advanced pancreatic cancer is established with gemcitabine 
monotherapy, all data to guide treatment options for patients 
progressed post Gem acquired resistance is limited. There 
is no standard therapeutic option for post Gem failure. The 
CONKO-3 study examined oxaliplatin, 5FU, LV combina-
tion (OFF) and 5FU, LV (FF) in 168 patients refractory to 
Gem.105 An overall survival improvement of two months in 
the OFF combination has been reported. A significant pro-
longation of PFS in the OFF schedule has been published (13 
weeks versus 9 weeks). Another phase III study randomized 
Gem refractory patients either to rubitecan or physicians 
individual choice.105,106 The study failed to show a statistically 
significant improvement in overall survival (3.7 months versus 
with bevacizumab, cetuximab with or without Gem has been 
studied by Ko et al.89 Fifty-seven patients were given both the 
antibodies and the rate response was 10.7% in the Gem arm, 
while no survival data have been published yet. Kindler et al 
in another phase II trial reconfirmed the results of Ko et al. 
The 139 patients studied were offered either Gem, erlotinib 
and bevacizumab or bevacizumab /cetuximab or Gem. No 
significant difference for overall survival or progression-free 
survival was reported.90
Bevacizumab failure in therapeutic trials addressed the 
need for other angiogenic inhibitors targeting the non VEGF 
pathways. Sorafenib, a multitargeted kinase inhibitor of VEG-
FR, platelet derived growth factor (PDGFR), c-kit, Rafl and 
Ftl3 was tested in a phase II trial but it was inactive.91 Axitinib, 
another multitargeted inhibitor of VEGFR and other kinase 
receptors, has been evaluated for its antitumor action with 
Gem in a phase II trial and a median survival of 6.9 months 
vs 5.6 months of the single agent Gem has been reported 
although the finding was not statistically significant.92 Phase 
III trials of axitinib combinations are ongoing. Aflibercept, 
a recombinant infusion protein inhibiting VEGF, another 
angiogenic inhibitor, is being examined in a phase III trial with 
Gem. Cilengitide inhibiting integrins is being investigated in 
a phase II trial in patients with advanced pancreatic cancer 
with Gem co- administration but no significant results have 
been shown.93 Other agents, against principal integrin recep-
tors α, β, like volociximab, are also in early phase trials with 
no published data so far.
O T H e R  P O T e N T I A L  
T H e R A P e U T I C  T A R G e T S
T H e  P I 3 K  A N D  A K T  PA T H wA y
The PI3K-AKT pathway is an important regulator of 
cell growth and survival. Increased dysregulation of many 
components of the pathway contributes to tumorigenesis. It 
is known that PI3K activates AKT, which has been implied in 
a multiple group of targets, including the transcription factor 
(NFKB) and the mammalian target of rapamycin (mTOR). 
The mTOR and NFKB are ideal targets of anticancer novel 
agents based on the fact that AKT is amplified and the PI3K 
AKT pathway is found activated in 20% and 59% of pancreatic 
cancer. Temsirolimus, an mTOR inhibitor, and curcumin, an 
NFKB inhibitor, have been evaluated in anticancer pancre-
atic treatments with the front line therapy containing Gem. 
Temsirolimus has been of limited efficacy when used in 
patients with advanced disease. Other antineoplastic agents, 
like everolimus and sirolimus, are currently tried in phase II 
trials.94-96 Curcumin, the NFKB inhibitor, is involved in the 
expression of regulated gene products such as BcL2, BclXL, 
COX2, CyclineD1 and Survivin (all defined as aniti-apoptotic 
proteins). Unfortunately combination with Gem did not man-
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3.1 months). Cartwright et al examined in a phase II trial the 
capecitabine administration in 41 patients with measurable 
disease post Gem single agent prior treatment.107 Three of 
the 41 patients presented an objective partial response and 
the overall survival rate was 9.5%. Another phase II trial ex-
amined capecitabine administration but in combination with 
oxaliplatin in a second line setting. Of the 39 enrolled patients, 
one presented a minimal partial response and ten patients 
had stable disease. The median overall survival was 23 weeks 
and PFS was 9.9 weeks. Second-line treatment options used 
in trials conducted are fraught with problems such as small 
number of patients enrolled and a major difficulty of the abil-
ity to compare the trials. Problems regarding status adequate 
information about performance, disease and other factors 
with known impact on survival are difficult to be resolved. 
It is suggested that all patients with disease progression on 
first-line therapy should be enrolled to participate in clinical 
trials. Further randomized trials are needed in the future to in-
vestigate further therapeutic options for this dreadful disease.
O T H e R  R e L e v A N T  T H e R A P e U T I C 
O P T I O N S
Based on the observation that normal and malignant 
pancreatic tissues express estrogen and somatostatin recep-
tors, hormone manipulation in advanced disease has been 
suggested. Tamoxifen, as a single agent anti-estrogen blockage 
compound, has minimum efficacy with induced rates of overall 
response <10%. Three randomized placebo-controlled trials 
of tamoxifen versus placebo in advanced pancreatic cancer 
have not managed to demonstrate any survival benefit. 108-111 
Octreotide has been studied in 2 randomized phase II trials as 
somatostatin receptor inhibitor but neither the standard dose 
of octreotide nor its combination with 5FU when compared 
to placebo demonstated any survival benefit.112-114
P R A C T I C e  G U I D e L I N e  F O R  L O C A L L y 
A D v A N C e D  P A N C R e A T I C  C A N C e R
Patients with locally advanced pancreatic cancer and ad-
equate performance status should be considered to undergo 
gemcitabine-based chemotherapy either with concomitant use 
of oxaliplatin or with capecitabine, based on the aggressive 
therapeutic value of the combination schedule. Gemcitabine 
with the tyrosine kinase inhibitor erlotinib is a reasonable 
therapeutic combined option with no extremely adverse 
toxicity profile in patients of good performance status and 
hereditary risk factors (BRCA, PALB2 mutations). On the 
basis of refractory to gemcitabine or recurrent disease, fluo-
ropyrimidines analogues with platinum-based combination or 
5FU/LV regimens should be tried with the view of palliation 
care in case of prior treatment failure or poor performance 
status. The possibility of induction in clinical trials may be 
considered for patients with high risk factors or poor cor-
respondence to first line treatment setting.
C O N C L U S I O N
Pancreatic cancer remains a surprisingly chemoresistant 
disease. Therapeutic options are still limited. Gemcitabine, 
the only FDA approved chemotherapeutic agent, has been 
thoroughly tried alone or in combination with other drugs but 
no further clinical benefit has been measured and a very mod-
est survival benefit has been achieved. A large variety of novel 
agents targeting molecular signalling pathways combined with 
one another or with cytotoxic drugs may offer a great promise 
in the future. Among the key molecular pathways involved, 
only the EGFR tyrosine kinase inhibitor, erlotinib, has been 
demonstrated with a significant survival benefit. Further in-
vestigation of signal transduction and embryonic pathways and 
clarification of the implicated role of cancer stem cells, should 
be done. Future development of targeted therapeutic options 
should focus on blockade of multiple signalling pathways at 
different levels to maximize the achieved benefit of the novel 
therapeutic agents.
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